EPZM Epizyme Inc

Price (delayed)

$10.19

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.29

Enterprise value

$1.1B

Sector: Healthcare
Industry: Biotechnology

Highlights

The gross profit has plunged by 55% YoY but it has grown by 27% from the previous quarter
The company's revenue rose by 35% QoQ but it fell by 34% YoY
EPZM's debt has soared by 163% from the previous quarter
The equity has contracted by 44% YoY and by 24% from the previous quarter

Key stats

What are the main financial stats of EPZM
Market
Shares outstanding
101.79M
Market cap
$1.04B
Enterprise value
$1.1B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.6
Price to sales (P/S)
65.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
70.09
Earnings
Revenue
$15.76M
EBIT
-$226.9M
EBITDA
-$222.91M
Free cash flow
-$257.22M
Per share
EPS
-$2.29
Free cash flow per share
-$2.55
Book value per share
$1.82
Revenue per share
$0.16
TBVPS
$4.23
Balance sheet
Total assets
$473.57M
Total liabilities
$288.68M
Debt
$235.74M
Equity
$184.9M
Working capital
$361.69M
Liquidity
Debt to equity
1.28
Current ratio
9.33
Quick ratio
8.68
Net debt/EBITDA
-0.3
Margins
EBITDA margin
-1,414.2%
Gross margin
67.9%
Net margin
-1,470%
Operating margin
-1,430.1%
Efficiency
Return on assets
-53.4%
Return on equity
-87.2%
Return on invested capital
-66.9%
Return on capital employed
-52.7%
Return on sales
-1,439.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EPZM stock price

How has the Epizyme stock price performed over time
Intraday
-2.11%
1 week
-7.78%
1 month
-11%
1 year
-52.91%
YTD
-6.17%
QTD
-6.17%

Financial performance

How have Epizyme's revenue and profit performed over time
Revenue
$15.76M
Gross profit
$10.7M
Operating income
-$225.42M
Net income
-$231.69M
Gross margin
67.9%
Net margin
-1,470%
EPZM's net margin has plunged by 105% YoY but it is up by 23% from the previous quarter
Epizyme's operating margin has shrunk by 92% YoY but it has increased by 24% QoQ
The gross profit has plunged by 55% YoY but it has grown by 27% from the previous quarter
The net income has contracted by 36% YoY and by 4.4% from the previous quarter

Growth

What is Epizyme's growth rate over time

Valuation

What is Epizyme stock price valuation
P/E
N/A
P/B
5.6
P/S
65.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
70.09
The EPS has decreased by 19% YoY and by 2.2% from the previous quarter
The equity has contracted by 44% YoY and by 24% from the previous quarter
The stock's P/B is 33% above its 5-year quarterly average of 4.2 and 6% above its last 4 quarters average of 5.3
EPZM's P/S is 36% below its 5-year quarterly average of 101.5 and 31% below its last 4 quarters average of 95.0
The company's revenue rose by 35% QoQ but it fell by 34% YoY

Efficiency

How efficient is Epizyme business performance
The ROS has plunged by 93% YoY but it has increased by 24% from the previous quarter
Epizyme's ROE has plunged by 69% YoY and by 19% from the previous quarter
The ROA has contracted by 21% YoY
EPZM's ROIC is up by 9% since the previous quarter

Dividends

What is EPZM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EPZM.

Financial health

How did Epizyme financials performed over time
The total assets is 64% more than the total liabilities
The total assets has grown by 24% from the previous quarter and by 12% YoY
The quick ratio has contracted by 22% YoY but it has grown by 6% from the previous quarter
EPZM's debt is 28% more than its equity
The equity has contracted by 44% YoY and by 24% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.